Neuroimmunology

Emerging data from AAN 2026 across neuroimmunology, epilepsy, neuromuscular disease, movement disorders and neuroinfectious disease highlighted the continued evolution of neurology toward more precise, personalized and mechanism-driven care. The American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, from April 18–22, 2026, ...

New findings highlight the importance of functional antiviral immunity, beyond lymphocyte expansion alone, in progressive multifocal leukoencephalopathy. At American Academy of Neurology 2026, Dr Yair Mina (Staff Clinician, Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, ...

New international data support rapid aquaporin-4 antibody testing to improve earlier diagnosis and access to care in NMSOD Accurate and timely antibody testing remains central to improving outcomes in neuromyelitis optica spectrum disorder (NMOSD), where early diagnosis can help prevent ...

The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...

Prof. Michael Levy highlights the first positive phase 3 trial in MOGAD and what it could mean for future standards of care. Relapse prevention remains one of the greatest unmet needs in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), where recurrent inflammatory ...

Understanding multiple sclerosis (MS) across the lifespan has become increasingly important as insights from adult disease cohorts reshape concepts of susceptibility, progression and long-term treatment strategy. In this Q&A, Dr Bardia Nourbakhsh (Johns Hopkins School of Medicine, Baltimore, ...

The 19th European Headache Congress (EHC25) was held in Lisbon and brought together headache specialists, researchers and healthcare professionals from across Europe and beyond. Under the theme Transforming challenges into solutions, the congress focused on translating advances in headache science into meaningful improvements in clinical care. The meeting addressed key challenges in the prevention, diagnosis and treatment of headache and facial pain disorders, with an emphasis on bridging basic science, translational research and real-world clinical practice.

Late-breaking data presented during the LB1: Late-Breaking Research and Clinical Trials session at ACTRIMS Forum 2026, February 5-7, 2026, San Diego, CA, USA, highlighted both progress and persistent challenges across multiple sclerosis (MS) and related neuroimmunological disorders. The session featured studies spanning ...

“The Pathways to Cures roadmap was built through global consensus so we can focus on the most impactful research to end MS.” - Bruce Bebo, National MS Society The Pathways to Cures roadmap represents one of the most coordinated global ...